Ducentis BioTherapeutics Ltd

With success in a second Phase III trial of its topical formulation of roflumilast in atopic dermatitis, Arcutis Biotherapeutics, Inc. moved closer to seeking a supplemental approval of Zoryve (rofl

Just over a month after getting US approval for Zoryve, a topical cream for psoriasis, Arcutis Biotherapeutics, Inc. is now targeting atopic dermatitis with the proposed purchase of the UK's Ducent